FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease, Endocrine |
| Therapuetic Areas: | Endocrinology, Nephrology / Urology |
| Healthy: | No |
| Age Range: | 6 - 21 |
| Updated: | 4/21/2016 |
| Start Date: | October 2009 |
| End Date: | June 2015 |
FGF-23 is a newly described protein that is an important regulator of phosphorus in the
body. This protein increases in people with kidney disease and people who need dialysis have
very high levels of FGF-23 in the blood. However, although some studies have indicated that
FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can
be lowered in patients with kidney disease by preventing them from absorbing phosphorus from
food. This study is designed to see what happens to levels of FGF-23 in the blood when
patients with chronic kidney disease take medications to prevent phosphorus absorption.
Since high levels of FGF-23 have been linked with increased rates of death in patients with
advanced kidney disease, controlling the levels may, in the future, be a way to decrease
heart disease in patients with kidney disease.
body. This protein increases in people with kidney disease and people who need dialysis have
very high levels of FGF-23 in the blood. However, although some studies have indicated that
FGF-23 levels go up with increased intake of phosphorus, no one knows if FGF-23 levels can
be lowered in patients with kidney disease by preventing them from absorbing phosphorus from
food. This study is designed to see what happens to levels of FGF-23 in the blood when
patients with chronic kidney disease take medications to prevent phosphorus absorption.
Since high levels of FGF-23 have been linked with increased rates of death in patients with
advanced kidney disease, controlling the levels may, in the future, be a way to decrease
heart disease in patients with kidney disease.
Inclusion Criteria:
- Inclusion criteria include pediatric patients, between the ages of 2 and 21 years,
with CKD stages 2-4 (GFR 15-90 ml/min/1.73m2).
Exclusion Criteria:
- Exclusion criteria include: the use of phosphate binder therapy within the past 3
months, treatment with 25(OH)vitamin D or 1,25dihydroxyvitamin D, underlying
metabolic bone disease, or underlying renal phosphate wasting disorder.
We found this trial at
1
site
UCLA UCLA's primary purpose as a public research university is the creation, dissemination, preservation and...
Click here to add this to my saved trials
